D-cycloserine Augmentation of Cognitive Remediation in Schizophrenia

Completed · Not applicable · Has a placebo group

Conditions studied: Schizophrenia

In brief

This study seeks to examine the effects of D-cycloserine augmentation on cognitive remediation for patients diagnosed with schizophrenia. We will test the hypotheses that D-cycloserine will significantly improve cognitive performance, negative symptoms, and measures of functioning compared to placebo when combined with eight weeks of cognitive remediation. We expect that these effects will persist when assessed at six-month follow up.

Key facts

Study ID

NCT00963924

Run by

Massachusetts General Hospital

People needed

54

Starts

2009-08-01

Expected to finish

2011-06-01

Last updated by the study team

2018-02-06

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Male or female
• Age 18-65 years
• Diagnosis of schizophrenia or schizoaffective disorder, depressed type
• Stable dose of antipsychotic for at least 4 weeks
• Able to provide informed consent
• Able to complete a cognitive battery
• Able to perform the cognitive remediation exercises

You may not qualify if…

• Current treatment with clozapine
• Dementia
• Seizure disorder
• Unstable medical illness
• Renal insufficiency measured as eGFR >60mg/dL/min
• Active substance abuse: positive urine toxic screen
• Pregnancy, nursing, or unwilling to use appropriate birth control measures during participation if female and fertile.

Where it is running

• Massachusetts General Hospital — Boston, Massachusetts, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.